/ORXOF

ORXOF Stock - Orexo AB (publ)

Q: What is the analyst price target for ORXOF?

Analyst price target information is not currently available for ORXOF.

Q: What is ORXOF's market cap?

Market capitalization information is not currently available for ORXOF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$2.90-10.22%

$0.33 (-10.22%) • Jan 12

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.19

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ORXOF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.90

52W High$3.23

52W Low$1.08

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$590.00M	$638.80M	$624.30M	$565.00M	$663.60M
Gross Profit	$517.90M	$549.90M	$521.70M	$486.10M	$598.00M
Gross Margin	87.8%	86.1%	83.6%	86.0%	90.1%
Operating Income	$-140,300,000	$-109,500,000	$-214,200,000	$-224,900,000	$-22,100,000
Net Income	$-203,000,000	$-128,300,000	$-177,600,000	$-223,500,000	$-84,400,000
Net Margin	-34.4%	-20.1%	-28.4%	-39.6%	-12.7%
EPS	$-5.89	$-3.73	$-5.17	$-6.51	$-2.45

Company Overview

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Visit Website

Earnings History & Surprises

ORXOF

Beat Rate

44%

Last 18 quarters

Avg Surprise

-28.0%

EPS vs Estimate

Beats / Misses

8/10

Last 12 quarters

Latest EPS

$-0.01

Q4 2025

EPS Surprise History

Q1 24

-15.1%

$-0.05vs$-0.05

Q2 24

+66.9%

$-0.02vs$-0.07

Q3 24

-162.1%

$-0.10vs$-0.04

Q4 24

-63.3%

$-0.12vs$-0.07

Q1 25

-105.2%

$-0.30vs$-0.15

Q2 25

+61.3%

$-0.05vs$-0.12

Q3 25

-176.4%

$-0.11vs$-0.04

Q4 25

+81.7%

$-0.01vs$-0.05

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 5, 2026	—	—	—	—
Q4 2025	Oct 23, 2025	$-0.05	$-0.01	+81.7%	✓ BEAT
Q3 2025	Jul 15, 2025	$-0.04	$-0.11	-176.4%	✗ MISS
Q2 2025	May 5, 2025	$-0.12	$-0.05	+61.3%	✓ BEAT
Q1 2025	Feb 6, 2025	$-0.15	$-0.30	-105.2%	✗ MISS
Q4 2024	Oct 24, 2024	$-0.07	$-0.12	-63.3%	✗ MISS
Q3 2024	Jul 17, 2024	$-0.04	$-0.10	-162.1%	✗ MISS
Q2 2024	May 8, 2024	$-0.07	$-0.02	+66.9%	✓ BEAT
Q1 2024	Mar 5, 2024	$-0.05	$-0.05	-15.1%	✗ MISS
Q3 2023	Sep 30, 2023	$-0.08	$-0.09	-4.7%	✗ MISS
Q2 2023	Jun 30, 2023	$-0.08	$-0.03	+60.3%	✓ BEAT
Q1 2023	Mar 31, 2023	$-0.22	$-0.18	+20.1%	✓ BEAT
Q1 2023	Jan 26, 2023	$-1.80	$-2.67	-48.3%	✗ MISS
Q4 2022	Nov 3, 2022	$-1.68	$-0.77	+54.2%	✓ BEAT
Q3 2022	Jul 14, 2022	$-1.20	$-1.04	+13.3%	✓ BEAT
Q2 2022	Apr 28, 2022	$-0.20	$-0.69	-245.0%	✗ MISS
Q1 2022	Jan 27, 2022	$-1.70	$-1.92	-12.9%	✗ MISS
Q4 2021	Nov 3, 2021	$-1.69	$-1.51	+10.7%	✓ BEAT
Q3 2021	Jul 15, 2021	$-1.55	$-2.15	-38.7%	✗ MISS

Frequently Asked Questions about ORXOF

What is ORXOF's current stock price?

Orexo AB (publ) (ORXOF) is currently trading at $2.90 per share. The stock has moved -10.22% today.

What is the analyst price target for ORXOF?

No analyst price targets are currently available for this stock.

What sector is Orexo AB (publ) in?

Orexo AB (publ) operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is ORXOF's market cap?

Orexo AB (publ) has a market capitalization of $0.10 billion, making it a small-cap company.

Does ORXOF pay dividends?

No, Orexo AB (publ) does not currently pay a dividend to shareholders.